Background: The pharmacodynamics of inhaled antimicrobials are poorly studied. Amikacin is being developed for inhalational therapy as BAY 41-6551.
Introduction
Infection is a leading cause of morbidity and mortality in critically ill patients in the ICU with infection occurring in 30%-45% in critical care. A high prevalence of infection in an ICU is linked to higher overall mortality and pulmonary infection accounts for 65% of all ICU infection. 1, 2 Mortality for critically ill patients with pulmonary infection is 25%-50%, and this is associated with more complications, longer ICU stay and increased healthcare costs. 3 The timely and precise administration of an antimicrobial agent is essential for successful therapeutic outcomes in pulmonary infection, 4 including reduction of the risk of development of antibiotic resistance, which remains an urgent public health and clinical problem in ICUs. Because there are few novel-action antimicrobial agents for Gram-negative infections in development pipelines, new approaches are required to (i) optimize therapeutic outcomes using existing drug classes, and (ii) suppress emergence of resistance to currently available agents. 5 Inhalational antibiotics represent one such new modality of care. Local administration into the lungs offers the advantages of very high local concentrations, reduces associated risks of emergence of resistance and, for some drug classes such as aminoglycosides, reduced systemic toxicity. 6 At present, inhaled antibiotics are not recommended for the therapy of ventilator-associated pneumonia as the evidence base is not strong enough 7 and inhaled antimicrobials have been regarded as controversial therapy but with potentially beneficial effects. 8, 9 Inhaled antibiotic pharmacokinetics in the lungs is affected by multiple factors such as the delivery system (nebulized/dry powder), tidal breaths, respiratory rate and presence of mucus or infection and antibiotics may be non-evenly distributed into the lung fields. 8 Amikacin Inhale (BAY 41-6551) is a combination of a special formulation of the aminoglycoside antibiotic with a proprietary liquid pulmonary technology delivery system. Phase II clinical studies in ventilated patients receiving 400 mg doses of amikacin The mean concentration was 2417 mg/L, standard error 688.75 mg/L, standard deviation 3644.50 mg/L, percentage coefficient of variation (%CV) 150.7%. The high inter-subject variability in the pharmacokinetics of amikacin inhaled is a characteristic of other inhaled antibiotics. The elimination half-life from ELF is unknown as the relevant studies have not been performed; however, amikacin clearance from bronchial secretions had a similar halflife to the blood. 13 In contrast, the half-life of inhaled levofloxacin in sputum was 55%-65% of that in serum.
14 At present, Phase III studies of inhaled solution amikacin as BAY 41-6551 are ongoing in the treatment of Gram-negative pneumonia (INHALE studies; www.clinicaltrials.gov).
The pharmacodynamics of systemic aminoglycosides is well known. They show concentration-dependent killing of Gramnegative bacteria in the therapeutic concentration range, have a persistent antibiotic effect of several hours, and the dominant pharmacodynamic index is AUC/MIC or C max /MIC. Protein binding in serum is low, hence for most purposes total and free drugs are equivalent. 15 A peak/MIC ratio of 8-10 has been shown in preclinical models to decrease the risk of selection of resultant subpopulations of Gram-negative bacteria and has been linked to optimized clinical outcome in humans. [16] [17] [18] The relevance of these pharmacodynamic factors to inhalational therapy-all of which apply to parenteral therapy-is not entirely clear, although the basic principles of drug action and resultant pharmacodynamic properties will apply. The MIC distributions of potential target pathogens indicate the vast majority of aerobic Gram-negative bacilli excluding Pseudomonas aeruginosa and Acinetobacter baumannii have MIC values of 64 mg/L (www. eucast.org; accessed February 2017).
The aim of this study was to use an in vitro pharmacokinetic model to simulate likely amikacin concentrations in ELF and establish for Gram-negative bacteria: (i) fAUC/MIC and fC max /MIC ratios for amikacin to produce bactericidal and bacteriostatic effects while suppressing resistant subpopulations, and (ii) provide descriptive data on the antibacterial effects and risks of emergence of resistance modelling median ELF concentrations and targeting pathogens with a range of amikacin MICs. Provision of these data will be helpful in conjunction with further pharmacokinetic and clinical trials outcome data in developing a clinical breakpoint specifically for inhaled amikacin.
Materials and methods

In vitro pharmacokinetic model
A Fermac 1000 (Electrolab, Gloucestershire, UK) in vitro pharmacokinetic model was used in dose-ranging experiments and to simulate total ELF concentrations associated with inhaled amikacin. The apparatus, which has been used many times before, consists of a single central chamber connected to a reservoir containing broth. The central chamber (360 mL) is connected to a collecting vessel for overflow. The contents of the central chamber were diluted with broth using a peristaltic pump (Ismatec, Cole Palmer, Hatfield, Herts, UK). The temperature was maintained at 37 C and broth in the central chamber agitated by a magnetic stirrer.
Media
One-hundred percent Mueller-Hinton broth was used in all experiments. Nutrient agar plates (Thermofisher Scientific, Basingstoke, UK) were used to recover organisms from the in vitro model. Amikacin was neutralized using P81 phosphocellulose paper. Amikacin at multiples of the MIC was added to nutrient agar plates in the studies on emergence of resistance.
Antibiotic
Amikacin was supplied by Bayer Healthcare (Leverkusen, Germany). Stock solutions were prepared according to the BSAC guidelines and stored at #70 C. 19 
MICs
MICs were determined by standard broth microdilution methods according to CLSI guidelines. Non-doubling dilutions were used to measure more accurately the MIC. 20 
Antibacterial effects
Experiments were performed at inoculum densities of 10 6 cfu/mL. For the 10 6 inoculum, 720 lL of a 10 9 cfu/mL bacterial suspension from an 18 h agar plate culture was added to the sample chamber 45 min before dosing. Samples were taken throughout the dosing period (48 h) to determine bacterial counts. Bacteria were quantified by using a spiral plater (Don Whitley Spiral Systems, West Yorkshire, UK). The minimum level of detection is 10 2 cfu/mL. Additional aliquots were stored at #70 C for measurement of amikacin concentrations using polarized fluoro-immunoassay methodology.
Emergence of resistance
Resistance to amikacin was assessed using population analysis profiles at time 0 (pre-exposure) and at 24 h intervals (post-exposure). 21 Samples were plated on to nutrient agar containing no antibiotic and amikacin at %1, %2, %4 and %8 the MIC to quantify resistant subpopulations. Bowker et al.
Pharmacodynamics and measurement of antibacterial effects
The antibacterial effects of amikacin were calculated by determining the log change in viable counts at 0, 1, 2, 3, 4, 5, 6, 12, 24, 36 and 48 h. The relationship between AUC/MIC or C max /MIC and antibacterial effects or emergence of resistance (EOR) was delineated using a Sigmoid Emax Model (Graph Prism, San Diego, CA, USA).
Dose-ranging studies
Nine strains of Enterobacteriaceae or P. aeruginosa were used; three Escherichia coli, three Klebsiella pneumoniae and three P. aeruginosa. Up to 10 exposures per strain were employed per strain with an amikacin t1 =2 of 1.1 h. Dose-ranging studies were conducted up to 48 h. The C max /MIC ranged from 0 to 80 and AUC/MIC from 0 to 500.
Simulation of human ELF concentrations
Nine strains were used; three strains of E. coli, three strains of P. aeruginosa (as above) and three strains of A. baumannii. ELF concentrations associated with amikacin (400 mg every 12 h) inhaled over 5 days (120 h) were modelled, i.e. C max 4045 mg/L at 0.5 h, C min 16.7 mg/L at 12 h and t1 =2 1.1 h, representing the mean C max and C min values of repeated doses over 9 days derived from the pharmacokinetic model of Stass et al. 22 All simulations were performed in triplicate. Pharmacodynamics of inhaled amikacin JAC Bowker et al.
Results
Pharmacokinetics
Amikacin concentrations were measured by competitive inhibition immunoassay using Indiko Plus V R QMS system (ThermoFisher, Hemel Hempstead, UK). The lower limit of detection is ,1.5 mg/L. The intra-day %CV was 1.53 and the inter-day %CV was 2.38 for a target value of 31.60 mg/L and %CV was 1.18 intra-day and %CV was 1.43 inter-day for a target value of 31.60 mg/L. Linear regression showed good correlation between target and measured concentrations from the simulations (R 2 " 0.9975). The target versus achieved amikacin concentrations are shown for the dose-ranging studies in Figure 1 . There was excellent agreement between target and achieved concentrations in both doseranging studies and ELF simulations.
Bacterial strains
Amikacin MICs for the E. coli strains (n " 3) were in the range 4-8 mg/L, for the K. pneumoniae strains (n " 3) 1.5-64 mg/L, for A. baumannii (n " 3) 2-32 mg/L and P. aeruginosa (n " 3) 2-192 mg/L. See Tables 1 and 2 .
Determination of fAUC/MIC and fC max /MIC ratios for bacteriostatic and bactericidal effects
The individual strain fAUC/MIC and fC max /MIC values for static, #1 log drop, #2 log drop antibacterial effects at times 12, 24 and 48 h are shown in Tables 1 and 3 and Figures 2-4 . The fAUC/MIC for 24 h static effect and #1 log drop were 51.0+26.7 and 71.6+27.6 for all nine strains of aerobic Gram-negative bacilli tested. For the individual species, the fAUC/MIC at 24 h to static effect and #1 log drop were 79.4+15.0 and 99.3+19.2 for E. coli (n " 3), 50.9+14.5 and 69.8+13.6 for K. pneumoniae (n " 3) and 22.7+2.7 and 45.6+18.1 for P. aeruginosa (Table 1 ). The fC max /MIC at 24 h for static effect and #1 log drop were 14.5+6.4 and 22.9+14.8 for all Enterobacteriaceae and P. aeruginosa (n " 9), 17.5+3.6 and 22.3+4.3 for E. coli (n " 3), 13.0+2.7 and 19.1+5.1 for K. pneumoniae (n " 3) and 12.9+11.1 and 27.2+14.8 for P. aeruginosa (n " 3). fAUC/MIC and fC max /MIC targets were lower at 12 h than at 24 h for a defined antibacterial effect, e.g. static effect and fAUC/MIC or fC max /MIC were larger at 48 h than 24 h for a similar antibacterial effect.
Emergence of resistance
Changes in population profiles at 24 and 48 h following exposure to amikacin in the dose-ranging studies are shown in Table 4 for E. coli, Table 5 for K. pneumoniae and Table 6 for P. aeruginosa. With E. coli there was some growth on MIC %4 plates at 24 h in the range 12-60 AUC/MIC, i.e. just below the 24 h AUC/MIC for static effect (Table 4) . With K. pneumoniae strain there was no growth on MIC %4 recovery media at 24 h, but there was growth in the range 0-60 at 48 h (Table 5 ) again mainly lower than the 48 h static effect target. In contrast with P. aeruginosa there was growth on MIC %4 recovery media at 24 h in the AUC/MIC range 12-80, which includes amikacin exposures linked to bactericidal effects at 24 h (Table 6) . With all three species (E. coli, K. pneumoniae, P. aeruginosa) there were greater changes in population profiles (growth at higher AUC/MIC values on MIC %4 plates and/or more growth on MIC %8 plates) at 48 h than 24 h, indicating the importance of time in increasing resistant bacterial populations. There was no growth on MIC %8 recovery plates.
Pharmacodynamics of inhaled amikacin
JAC
Amikacin MICs were performed on isolates recovered from population profiles. In general, isolates from MIC %4-8 recovery media had raised MICs (4% parent strain, data not shown).
ELF simulated concentrations
Nine strains (E. coli n " 3, A. baumannii n " 3, P. aeruginosa n " 3) were tested. The strain viable counts over the 120 h simulations are shown in Table 2 . For strains (E. coli n " 3, A. baumannii n " 1, P. aeruginosa n " 2) with amikacin MIC 8 mg/L there was rapid clearance (within 1 h) followed by no regrowth up to 120 h. For the 
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strains with MIC 32 mg/L (A. baumannii n " 2, P. aeruginosa n " 1) there was an initial 2-4 log kill followed by regrowth over 120 h. Strain MICs were related to the decrease in bacterial load at 24, 72 and 120 h. At 24 h, strains with MICs 180 mg/L would have at least a static effect and those with MIC 148 mg/L at least a #1 log drop in the viable count ( Figure 5 ).
Discussion
Pre-clinical data on the pharmacodynamics of aminoglycosides is surprisingly rare-at least until the publication of the recent USCAST document on setting aminoglycoside clinical breakpoints (www.uscast.org). Vogelman et al. 23 used a neutropenic thigh infection model and a single strain of P. aeruginosa to establish exposure-response relationships for tobramycin. A C max /MIC of 8 and an AUC/MIC 50-60 was linked to a 24 h static effect. For a #2 log reduction in bacterial load a C max /MIC ratio of 32 and AUC/MIC of 120-130 was required. Blaser et al. 16 studied netilmicin in a dilutional in vitro model against five pathogen strains, four of which were aerobic Gram-negative bacilli (two Enterobacteriaceae, two P. aeruginosa). A C max /MIC of 10 was linked to the 24 h static effect.
Finally, Nielsen et al. 24 used static-concentration time-kill curves to model the pharmacodynamics of gentamicin against a single strain of E. coli. A C max /MIC of 13 and AUC/MIC of 67 were linked to static effects. The recent USCAST consultation document 'Aminoglycoside In Vitro Susceptibility Test Interpretive Criteria Evaluations' (www.uscast.org; accessed 13 December 2016) presents data from the murine neutropenic thigh model where two K. pneumoniae, three E. coli, one Enterobacter cloacae and one Serratia marcescens were tested against gentamicin, tobramycin or amikacin. The AUC/MIC targets for 24 h stasis and #1 log and #2 log reductions in load were 31.1, 82.3 and 1170, respectively. A similar analysis was performed with five strains of P. aeruginosa and AUC/MIC targets for 24 h stasis and #1 log and #2 log reductions in bacterial load were 63.6, 90.9 and 140, respectively.
There are a number of clinical pharmacodynamic publications on aminoglycosides. Moore et al. 25 studied 236 patients with Gram-negative infection mainly Enterobacteriaceae, treated with gentamicin, tobramycin or amikacin. Clinical cure could be related to the C max /MIC ratio, although some patients also received b-lactam therapy. A C max /MIC of 8-10 was associated with 80% cure rate.
Kashuba et al. 17, 18 studied 78 patients with Gram-negative hospital-associated pneumonia mainly caused by P. aeruginosa. Clinical outcome was assessed by resolution of WBC and fever. Many patients also received active b-lactams. A C max /MIC of .10 in the first 48 h predicted .90% probability of resolution by day 7. Smith et al.
26 studied 23 patients with pneumonia or intraabdominal infection treated with tobramycin. An AUC/MIC ratio was shown to be predictive of success-the percentage of patients with clinical success if the AUC/MIC ratio was ,110 was 47% while if the AUC/MIC was .110 success this was seen in 80% of patients. Finally, Zelenitsky et al. 27 analysed 38 patients with a P. aeruginosa bloodstream infection with clinical cure as the measured endpoint. In a mixed analysis including aminoglycoside and ciprofloxacin therapy but complicated by b-lactam use, a C max /MIC of .10 optimized cure to .90%. There are no clinical or pre-clinical data on ELF pharmacodynamics related to inhaled aminoglycosides.
The data generated here using a single compartment dilutional model are compatible with the published data and the recent USCAST re-analysis of murine data (www.USCAST.org). Our data indicate that an AUC/MIC ratio of 50-70 is associated with a 24 h static effect. This is well aligned with the published data, which would suggest, based on a very limited number of strains, an AUC/MIC target of 50-70. 23, 24 A point of difference between our data and that of USCAST is that AUC/MIC ratios for static effect were lower for Enterobacteriaceae than P. aeruginosa in the animal model while the reverse was true in our data. Pharmacodynamics of inhaled amikacin JAC A C max /MIC of 10 seems to be predictive from published clinical data; however, our C max /MIC target for 24 h static on #1 log reduction in load in our models is higher, i.e. 10-30. It is clear that clinical studies are, however, limited as they are small, 26, 27 include mixed species of pathogen, include different sites of infection 23, 24 and often included other microbiologically active agents. 26, 27 That said, a translational target associated with a 24 h static to #1 log reduction in pathogen load would seem reasonable, i.e. an AUC/MIC of 50-70.
In vitro pharmacokinetic models have been used previously to model ELF concentrations of antibiotics; 28, 29 however, such approaches are not without problems. Perhaps most importantly the value of modelling tissue concentrations in making human predictions has not been validated to the degree reported with serum concentrations and ELF has never been used as a basis for setting clinical breakpoints. There are also concerns about modelling protein and other binding in ELF 30 and for inhalation therapy, in particular how the high observed pharmacokinetic variation in concentrations, may impact on clinical outcomes-particularly for less susceptible strains. Overall, therefore, in vitro simulations of ELF can only be taken as pointers to likely future efficacy in humans and contributory to possible clinical breakpoints related to inhalational treatment.
The ELF concentrations modelled 21 have also been employed in other in vitro models 31, 32 and predict higher ELF concentrations than those reported by Luyt et al. 12 However, the data used in the model included data from two Phase II clinical trials, and modelled a range of ethnic groups, ages and weights so may more accurately represent an ICU population. Given the pharmacokinetic variation, the exact concentrations modelled may not be critical in reaching conclusions of efficacy and further work may need to be conducted when more data become available from clinical trials.
Finally, simulation of mean amikacin concentrations generated by BAY 41-6551 in ELF after inhaled therapy would suggest a clinical breakpoint for susceptibility of 128 mg/L; however, pharmacokinetic variation would have an impact on this and clinical confirmation of the modelled ELF amikacin concentrations is needed.
